Norges Bank Protagonist Therapeutics, Inc Transaction History

Norges Bank

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$7.36 - $11.17 $1.09 Million - $1.66 Million	148,700 New	148,700 $1.62 Million
Q1 2021 May 07, 2021	SELL	$19.02 - $31.15 $212,263 - $347,634	-11,160 Closed	0 $0
Q4 2020 Mar 02, 2021	BUY	$18.49 - $25.13 $206,348 - $280,450	11,160 New	11,160 $225,000
Q4 2020 Feb 10, 2021	SELL	$18.49 - $25.13 $206,348 - $280,450	-11,160 Closed	0 $0
Q3 2020 Nov 12, 2021	BUY	$15.19 - $22.4 $169,520 - $249,983	11,160 New	11,160 $218,000

247

56.4M

76.3K

114K

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $2B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

Get notified when there are updates to the investment portfolio of Norges Bank, based on Form 13F filings with the SEC.

Stay updated on Norges Bank with notifications on news.